Global /Australia /Healthcare /Biotechnology /IXC

Invex Therapeutics Ltd.

IXC

• ASX: IXC • Delayed

0.1300AUD 0%

0.0916 USD

As of 14 June 2026, Invex Therapeutics Ltd. has a market cap of $6.87M USD, ranking #43148 globally and #1460 in Australia. It ranks #3816 in the Healthcare sector, and #749 in the Biotechnology industry.

Global Rank

43148

Country Rank

1460

Sector Rank

3816

Industry Rank

749

Key Stats

Market Cap

$6.87MUSD

9.77M AUD

Enterprise Value

$3.65MUSD

5.17M AUD

Revenue (TTM)

$161.03KUSD

229.08K AUD

Net Income (TTM)

-$587.57KUSD

-835.92K AUD

PS Ratio

42.6

PB Ratio

2.1

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Biotechnology

Founded

2019

Website

invextherapeutics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	30%	30%	8.3%	-10%	8.3%	73%	-71%	-82%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	IXC Invex Therapeutics Ltd Ordinary Shares ISIN: AU0000048621 Shares Out.: Shares Outstanding: 75.154M¹ Shares Float: 74.847M² TV: TradingView: ASX: IXC SA: Stock Analysis: ASX: IXC YF: Yahoo Finance: IXC.AX GF: Google Finance: ASX: IXC BA: Barron's: IXC MS: Morningstar: XASX: IXC	0.1300 AUD	TV: TradingView: ASX: IXC SA: Stock Analysis: ASX: IXC YF: Yahoo Finance: IXC.AX GF: Google Finance: ASX: IXC BA: Barron's: IXC MS: Morningstar: XASX: IXC

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Invex Therapeutics Ltd.

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, Australia.

Similar Companies

Industry: Biotechnology (Australia)

Name	Market Cap (USD) diff.	PE	Country
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 617K%	29.3	Australia
Telix Pharmaceuticals Ltd. ASX: TLX	$3.58B 5.09B AUD 52K%	-	Australia
Mesoblast Ltd. ASX: MSB	$2.02B 2.88B AUD 29K%	-	Australia
PolyNovo Ltd. ASX: PNV	$490.46M 697.75M AUD 7K%	71.8	Australia
Kazia Therapeutics Ltd. NASDAQ: KZIA	$141.64M 2K%	-	Australia
Immutep Ltd. ASX: IMM	$65.26M 92.84M AUD 850%	-	Australia

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 3M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 2M%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 697K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 653K%	35.5	South Korea
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 616K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 409K%	43.8	South Korea

chevron_leftBack